SCHEMBL16712960

SCHEMBL16712960

CN1CCC(Oc2ccc(Nc3ccc(NC(=O)c4ccc(C(C)(C)C)cc4)cc3)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 0.52
MAPT P10636 4/20 0.49
LMNA P02545 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 3/20 0.47
USP2 O75604 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LCK P06239 1/20 0.47
KDR P35968 1/20 0.47
MAPK14 Q16539 1/20 0.47
GSK3B P49841 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701384 0.93 TRPV1 (0.52) TRPV1MAPTLMNAHDAC3HDAC11
SCHEMBL23970008 0.89 RAB9A (0.56) MAPTLMNARAB9ANPC1SMN1; SMN2
SCHEMBL16712951 0.89 RAB9A (0.62) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL16712973 0.88 RAB9A (0.62) RAB9ANPC1LCKKDRMAPK14
SCHEMBL16701473 0.83 ADORA3 (0.51) TRPV1MAPTLMNAHDAC3HDAC8
SCHEMBL16712952 0.83 RAB9A (0.61) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL16702122 0.82 SCN1A (0.57) RAB9ANPC1LCKKDRMAPK14
SCHEMBL16701407 0.82 RAB9A (0.56) MAPTLMNARAB9ANPC1SMN1; SMN2
SCHEMBL16701940 0.82 RAB9A (0.62) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL16701405 0.81 RAB9A (0.62) RAB9ANPC1LCKKDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3066072-B1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIV KANSAS (US) 2021-11-03 EP disclosed
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors UNIVERSITY OF KANSAS (US) 2020-06-23 US disclosed
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS UNIVERSITY OF KANSAS (US) 2016-09-22 US disclosed
WO-2015070091-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS THE UNIVERSITY OF KANSAS (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689344-B2 Biphenylamide derivative Hsp90 inhibitors HSP90AB1, HSP90AA1, HSP90AB2P TRPV1 3393/4885MAPT 1299/4885LMNA 1927/4885
US-20160272584-A1 BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P TRPV1 3393/4885MAPT 1299/4885LMNA 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.